Novo Nordisk A/S (NYSE:NVO) Q4 2023 Earnings Call Transcript

Daniel Bohsen: Good. Martin, any brief comment on amycretin?

Martin Lange: Yes. So very high level short answer is yes. Obviously, if we have the aspiration to have differentiated products, amycretin, oral amycretin, has to be in the range of where we see efficacy and safety with CagriSema.

Daniel Bohsen: Thank you, Martin. And Doug, over to you. Any comments on our competitive commercial strategy in light of a competitor movement?

Doug Langa: What I would say is I’d bring it back to us and say, we believe in the foundation that we have in NovoCare and there’s lots of elements to that. So we’ll continue to stay focused on that and appreciate the question.

Daniel Bohsen: Thank you, Michael. Thank you, Doug, for the answer. This concludes the Q&A session. Thank you for participating, and please feel free to reach out to investor relations if you have any follow-up questions.

Daniel Bohsen: Before we close the call, as always, I would like to hand over to you, Lars, for the final remarks.

Lars Fruergaard Jorgensen: Yes. Thank you, Daniel. And also, thank you from me for all participating today. I hope it’s clear that we are very pleased with our performance in the past year and equally excited about what we can do in 2024 based on the attractive guidance range we have put forward. A lot of focus on scaling capacities with some real, tangible backing of our scaling in the form of now more than doubling the start doses in the U.S., and we look to continuously expand our capacity and equally important, the expansion of our pipeline and really doubling down on our strongholds in diabetes, obesity, but also increasingly cardiovascular disease. So we’re excited about how the pipeline is shaping up. So thank you all for your attention today and we look forward to seeing you in the near future. Bye-bye.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.